Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Restaxil is a natural, over-the-counter (OTC) homeopathic medicine developed and marketed by PharmaSGP for the treatment of neuralgic (nerve) pain. It is available in two primary formulations: an oral liquid (drops) and a topical gel (Restaxil Nervenschmerzgel). The liquid formulation contains a complex of five homeopathic active ingredients: *Gelsemium sempervirens* (D2), *Spigelia anthelmia* (D2), *Iris versicolor* (D2), *Cyclamen purpurascens* (D3), and *Cimicifuga racemosa* (D2). The gel formulation utilizes a dual complex of *Iris versicolor* (D2) and *Spigelia anthelmia* (D2). As a homeopathic product, it operates on the principle of high dilution and does not have a defined conventional pharmacological mechanism of action or specific biological target. It is indicated for various forms of nerve pain, including sciatica, radiating back pain, and pain associated with shingles or fibromyalgia. Restaxil is primarily marketed in Germany and Austria, where it is a leading brand in the systemic chemical-free OTC pain relief market.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Restaxil.